Modality
Nanobody
MOA
PRMT5i
Target
CD123
Pathway
Ferroptosis
CholangiocarcinomaBCC
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
Jul 2017
→ Nov 2027
Phase 3Current
NCT06916577
2,927 pts·BCC
2017-12→2027-11·Completed
NCT05313265
2,177 pts·BCC
2017-07→2027-06·Active
5,104 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-12-269mo awayConference· Cholangiocarcinoma
2027-06-271.2y awayPh3 Readout· BCC
2027-11-211.6y awayPh3 Readout· BCC
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Active
P3
Complet…
Catalysts
Conference
2026-12-26 · 9mo away
Cholangiocarcinoma
Ph3 Readout
2027-06-27 · 1.2y away
BCC
Ph3 Readout
2027-11-21 · 1.6y away
BCC
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP |